Necuparanib

Drug Profile

Necuparanib

Alternative Names: M-402; M-ONC 402; M402 heparan sulfate

Latest Information Update: 05 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Momenta Pharmaceuticals
  • Class Antineoplastics; Glycosaminoglycans; Sugar alcohols; Uronic acids
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pancreatic cancer

Most Recent Events

  • 04 Aug 2016 Momenta discontinues patient enrolment in a phase II trial in Pancreatic cancer (Combination therapy, Late-stage) due to lack of efficacy data
  • 04 Jun 2016 Efficacy, adverse events and pharmacokinetics data from a phase I/II trial in pancreatic cancer (First line therapy, Combination therapy, Metastatic disease) presented at the American Society of Clinical Oncology Annual meeting (ASCO-2016)
  • 21 Dec 2015 Momenta Pharmaceuticals re-initiates enrolment in the phase II MOM-M402-103 trial for Pancreatic cancer (First line therapy, Combination therapy, Metastatic disease) in USA and Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top